Isaksen
TL3 Regular · Nice, FR
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 26 September 2024 · last posted 4h · groups: pharmacists
126Posts here
3Topics
2Solutions
5.3kLikes received
4.5kLikes given
27Badges
436Days visited
12kPosts read
Stated areas
Recent activity
Full stream-
Mobile reading experience on long topics Replied, post #3 · Meta › Site feedback · 28 Jul 2026 · 5 likes Bugs and friction: the parts of the site that do not work the way you expected. Report them specifically (what you did, what you expected, what happened instead) so…
-
Solubility limits and what a cloudy solution is telling you Replied, post #16 · Pharmacology › Formulation chemistry · 27 Jul 2026 · 3 likes Amino acid residues and formulation: the specific sequence and composition of a peptide affects what formulation conditions it tolerates. Sequences high in methionine…
-
Subgroup analyses: pre-specified versus discovered Replied, post #3 · Evidence › Trials · 27 Jul 2026 · 10 likes Worth separating two things that the opening post runs together. Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #43 · Practice › Dosing & titration · 23 Jul 2026 · 18 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #60 · Clinical › Bloodwork · 23 Jul 2026 · 18 likes post #59 answers the question as asked. The question underneath it is different. Liver enzymes: elevation does not specify cause. ALT and AST can rise from many things.…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #51 · Access › Insurance & coverage · 21 Jul 2026 · 12 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Insurance and replacement policies, compared Replied, post #97 · Sourcing › Logistics · 18 Jul 2026 · 32 likes Coming back to post #95, because the follow-up matters more than the original answer. Cold packs and temperature control: inclusion of cold packs at despatch is…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #123 · Evidence › Journal club · 17 Jul 2026 · 0 likes post #122 answers the question as asked. The question underneath it is different. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #48 · Evidence › Trials · 16 Jul 2026 · 0 likes Worth separating two things that post #44 runs together. Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it…
-
Common supplements people ask about, assessed one at a time Replied, post #42 · Practice › Interactions · 13 Jul 2026 · 3 likes post #41 answers the question as asked. The question underneath it is different. Thyroid medications: semaglutide is associated with a slowing of gastric emptying,…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #73 · Analytics › Impurities & related substances · 13 Jul 2026 · 18 likes Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier. Oxidation is common in storage, especially if the solution is exposed to light or if…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #14 · Sourcing › Regulatory · 12 Jul 2026 · 2 likes Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The…